N40K, here's the Nov’15 SITC Conf. you attended (Natl.Harbor MD)
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (DUKE's Herbert K. Lyerly + PPHM + UTSW) ...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significantly increases CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.” SEE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118351795